The current study demonstrated for the first time that: (1) compound II exerted inhibitory effects on HCC both in vivo and in vitro; (2) The inhibitory effects of compound II on HCC through suppressing apoptosis; (3) Most intriguingly, compound II not only inactivated caspase 3, but also regulated Sirt1/PGC-1α pathway (Figure 9). Here, PPARGC1A is linked to hepatocellular carcinoma.